To understand the immune infiltrate level of OS in a broader context, we compared immune infiltration scores (ESTIMATE) from our cohort against other tumor types profiled in The Cancer Genome Atlas (TCGA), the OS samples from the International Cancer Genome Consortium (ICGC) and TARGET studies, as well as four additional patients with metastatic OS who were treated with combination CTLA-4 blockade and PD-L1 blockade but exhibited no objective responses (Fig. 3a). Here, CTLA4 is linked to neoplasm.